Medicus Pharma’s (MDCX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a research note issued to investors on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $27.00 price target on the stock.

A number of other analysts also recently issued reports on the stock. Maxim Group lifted their price objective on shares of Medicus Pharma from $10.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Wall Street Zen raised shares of Medicus Pharma from a “sell” rating to a “hold” rating in a research report on Friday, May 30th. Finally, D Boral Capital raised shares of Medicus Pharma to a “strong-buy” rating in a research report on Monday, April 14th. One research analyst has rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $23.50.

Medicus Pharma Stock Performance

Shares of MDCX stock opened at $3.38 on Tuesday. The firm’s 50 day moving average price is $4.06 and its two-hundred day moving average price is $3.50. Medicus Pharma has a 52-week low of $1.80 and a 52-week high of $8.94. The stock has a market cap of $45.87 million and a PE ratio of -2.91.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.19). As a group, sell-side analysts predict that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Velocity Fund Partners, Lp sold 75,000 shares of the business’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $7.72, for a total value of $579,000.00. Following the completion of the sale, the insider directly owned 3,248,741 shares in the company, valued at $25,080,280.52. The trade was a 2.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Institutional Trading of Medicus Pharma

Large investors have recently modified their holdings of the stock. Interchange Capital Partners LLC bought a new position in shares of Medicus Pharma in the fourth quarter worth about $3,628,000. Armistice Capital LLC acquired a new position in Medicus Pharma during the 1st quarter worth approximately $4,710,000. Finally, Private Advisor Group LLC acquired a new position in Medicus Pharma during the 1st quarter worth approximately $211,000.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.